Dabrafenib (Tafinlar®, DB08912): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Market Profile

Section 1: Overview and Executive Summary

Dabrafenib is a highly potent and selective small-molecule inhibitor of BRAF serine/threonine kinases, representing a cornerstone of targeted therapy in modern oncology.[1] Its development and clinical application are predicated on the precise identification of activating mutations within the

BRAF gene, most notably the V600E and V600K variants, which function as oncogenic drivers in a diverse range of solid tumors.[3] Dabrafenib functions as a reversible, ATP-competitive inhibitor, specifically targeting these mutated kinases to block downstream signaling through the Mitogen-Activated Protein Kinase (MAPK) pathway, thereby inhibiting tumor cell proliferation and inducing apoptosis.[1]

The clinical utility and maximum therapeutic benefit of dabrafenib are realized almost exclusively when it is administered in combination with trametinib, a MEK inhibitor.[6] This dual blockade of the MAPK pathway at two distinct nodes—BRAF and MEK—constitutes a synergistic therapeutic strategy. This approach not only enhances the depth and durability of anti-tumor response but also critically mitigates a key mechanism of acquired resistance and a significant toxicity associated with BRAF inhibitor monotherapy: the paradoxical activation of the MAPK pathway in BRAF wild-type cells.[1]

The dabrafenib-trametinib combination has secured regulatory approval for a broad and expanding portfolio of indications. Its primary applications are in melanoma, where it is approved for the treatment of unresectable or metastatic disease and as an adjuvant therapy for high-risk, resected stage III disease.[1] Its use has extended to other malignancies driven by the same genetic alteration, including BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) and locally advanced or metastatic anaplastic thyroid cancer (ATC).[9] A landmark achievement in its development was the tumor-agnostic approval for any unresectable or metastatic solid tumor harboring a BRAF V600E mutation, a testament to the success of a biomarker-driven, rather than histology-specific, therapeutic strategy.[11] Furthermore, it has established a new standard of care in pediatric oncology for low-grade glioma (LGG) with a BRAF V600E mutation.[14]

The foundation of these approvals rests on a robust body of clinical evidence from pivotal trials, most notably the COMBI series (COMBI-d, COMBI-v, and COMBI-AD). These studies have consistently demonstrated statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and relapse-free survival (RFS) for the combination therapy compared to historical standards and BRAF inhibitor monotherapy.[3]

The safety profile of the combination therapy is well-characterized but requires diligent clinical management. Key adverse events of special interest include serious febrile reactions (pyrexia), which are more frequent and severe with the combination; cardiovascular toxicities such as cardiomyopathy (reduced ejection fraction); ocular toxicities like uveitis; and the risk of hemorrhage.[7] Proactive monitoring, patient education, and adherence to dose modification guidelines are essential for mitigating these risks.

Marketed by Novartis under the brand name Tafinlar®, dabrafenib is a significant commercial asset and a paradigm-shifting agent that exemplifies the success of precision oncology.[7] Its journey from a targeted therapy for a single cancer type to a broad, tumor-agnostic treatment underscores the power of targeting fundamental oncogenic drivers, transforming the prognosis for patients with BRAF V600-mutated cancers.

Section 2: Chemical Identity and Pharmaceutical Properties

This section provides the foundational chemical, physical, and pharmaceutical data for dabrafenib, establishing a clear and unambiguous identity for the active pharmaceutical ingredient and its marketed formulations.

Nomenclature and Identifiers

• Generic Name: Dabrafenib [1]
• Brand Names: Tafinlar®, Finlee® [1]
• Systematic (IUPAC) Name: N-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide [20]
• Synonyms and Development Codes: GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436B (mesylate salt) [1]
• Key Identifiers:
• DrugBank ID: DB08912 [1]
• CAS Number: 1195765-45-7 (free base) [2]; 1195768-06-9 (mesylate salt) [20]
• ATC Code: L01XE23 [9]
• ChemSpider ID: 25948204 [24]
• PubChem ID: 44462760 [25]
• UNII: QGP4HA4G1B [21]

Chemical and Physical Properties

• Chemical Formula: C23​H20​F3​N5​O2​S2​ (free base) [9]
• Molecular Weight: 519.56 g/mol (free base) [20]; 615.68 g/mol (mesylate salt, C23​H20​F3​N5​O2​S2​⋅CH4​O3​S) [4]
• Appearance: A white to off-white or slightly colored solid powder.[4]
• Solubility: Dabrafenib exhibits pH-dependent solubility. It is practically insoluble in aqueous media at a pH above 4 but is very slightly soluble at pH 1.[4] It is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF).[20] This solubility profile is clinically relevant, as changes in gastric pH could theoretically impact its dissolution and subsequent absorption.
• Melting Point: 214-216°C [20]
• Chemical Structure: The chemical structure of dabrafenib is provided below.

Pharmaceutical Formulations

Dabrafenib is formulated for oral administration to facilitate its use in outpatient settings. To accommodate different patient populations, particularly pediatric patients, multiple formulations are available:

• Capsules: Supplied as 50 mg and 75 mg hard capsules for oral administration. Each capsule contains dabrafenib mesylate equivalent to the stated amount of dabrafenib free base.[3]
• Tablets for Oral Suspension: Supplied as 10 mg tablets that can be dispersed in water to form an oral suspension. This formulation is critical for administering accurate, weight-based doses to pediatric patients who cannot swallow capsules.[4]

The inactive ingredients in the capsules include colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. The capsule shells are composed of hypromellose, red iron oxide (E172), and titanium dioxide (E171).[4] The tablets for oral suspension contain additional excipients, including acesulfame potassium, artificial berry flavor, mannitol, and crospovidone, to improve palatability and dispersion.[4]

Table 1: Key Physicochemical and Identification Properties of Dabrafenib

Property	Value	Source(s)
Generic Name	Dabrafenib	1
Brand Name	Tafinlar®, Finlee®	1
IUPAC Name	N-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide	20
DrugBank ID	DB08912	1
CAS Number	1195765-45-7 (free base)	2
	1195768-06-9 (mesylate salt)	20
ATC Code	L01XE23	9
Molecular Formula	C23​H20​F3​N5​O2​S2​	9
Molecular Weight	519.56 g/mol (free base)	20
	615.68 g/mol (mesylate salt)	4
Appearance	White to off-white solid	4
Solubility	Soluble in DMSO; practically insoluble in aqueous media above pH 4	4

Section 3: Preclinical and Clinical Pharmacology

This section details the molecular basis of dabrafenib's therapeutic action, its effects on cellular pathways, and its pharmacokinetic profile, which collectively govern its clinical efficacy and safety.

3.1 Mechanism of Action (MoA)

The therapeutic effect of dabrafenib is rooted in its highly specific interaction with the Mitogen-Activated Protein Kinase (MAPK) signaling cascade, a central pathway regulating cell growth, differentiation, and survival.[1]

Targeted Inhibition of BRAF Kinase

Dabrafenib is a reversible, ATP-competitive inhibitor of the serine/threonine-protein kinase B-raf (BRAF).[1] In normal cellular physiology, the MAPK pathway (also known as the RAS/RAF/MEK/ERK pathway) is tightly regulated. Upon activation by upstream signals, RAS activates RAF kinases (A-RAF, B-RAF, C-RAF), which in turn phosphorylate and activate MEK1 and MEK2. MEK then phosphorylates and activates ERK1 and ERK2, which translocate to the nucleus to regulate gene expression related to cell proliferation and survival.[3]

Selectivity for V600 Mutations

The defining characteristic of dabrafenib is its potent and selective inhibition of mutated forms of BRAF kinase, which are found in a significant proportion of certain cancers, including approximately 50% of melanomas.[3] Specific somatic point mutations in the

BRAF gene, such as V600E (a valine to glutamic acid substitution at codon 600), V600K (valine to lysine), and V600D (valine to aspartic acid), result in a constitutively active BRAF protein. This aberrant, persistent activation of the MAPK pathway drives uncontrolled cellular proliferation and tumor growth.[3]

Dabrafenib exhibits high affinity for these mutated kinases. In vitro cell-free assays have demonstrated potent inhibitory activity, with half-maximal inhibitory concentrations (IC50​) in the low nanomolar range: 0.65-0.8 nM for BRAF V600E, 0.5 nM for BRAF V600K, and 1.84 nM for BRAF V600D.[2] This potency is significantly greater than its activity against wild-type BRAF (

IC50​ of 3.2-5.2 nM) and the related c-RAF kinase (IC50​ of 5.0-6.3 nM).[2] This selectivity for the mutated oncoprotein over its wild-type counterpart provides the therapeutic window, allowing for targeted inhibition of cancer cells while relatively sparing normal tissues.

Paradoxical MAPK Pathway Activation and the Rationale for Combination Therapy

A critical and defining feature of the BRAF inhibitor drug class, including dabrafenib, is the phenomenon of paradoxical MAPK pathway activation. In cells that are BRAF wild-type but may harbor an upstream mutation (e.g., in RAS), the binding of a BRAF inhibitor can induce a conformational change that promotes the dimerization and transactivation of RAF kinases, leading to an unexpected increase in downstream MEK and ERK signaling.[10] This paradoxical activation is the direct molecular mechanism underlying the high incidence of hyperproliferative skin lesions, such as cutaneous squamous cell carcinoma (cuSCC), keratoacanthomas, and papillomas, observed in patients treated with dabrafenib monotherapy.[11]

This mechanism-based toxicity provided the compelling scientific rationale for the development of combination therapy. By co-administering dabrafenib with trametinib, a selective inhibitor of the downstream kinases MEK1 and MEK2, the therapeutic strategy achieves two crucial goals. First, it creates a more profound and durable vertical blockade of the MAPK pathway in BRAF-mutant tumor cells, which can enhance anti-tumor efficacy and delay the onset of acquired resistance.[1] Second, in BRAF wild-type cells (such as those in the skin), the MEK inhibition by trametinib effectively abrogates the paradoxical signal generated by dabrafenib, thereby significantly reducing the incidence of BRAF inhibitor-induced cutaneous malignancies.[5] This transformation of a dose-limiting toxicity into a justification for a more effective combination represents a landmark example of rational drug development in oncology.

3.2 Pharmacodynamics

The pharmacodynamic effects of dabrafenib are consistent with its mechanism of action as a targeted BRAF inhibitor.

• In Vitro Activity: In laboratory studies, dabrafenib effectively inhibits the growth of a wide range of cancer cell lines that express BRAF V600E mutations, with 50% growth inhibition (GI50​) values typically below 200 nM.[5] Treatment of these cells with dabrafenib leads to a measurable decrease in the phosphorylation of the downstream MAPK pathway effectors MEK and ERK. This pathway inhibition ultimately triggers programmed cell death, or apoptosis, as evidenced by the activation of executioner caspases 3 and 7.[5]
• In Vivo Activity: In preclinical animal models, orally administered dabrafenib demonstrates significant anti-tumor activity, reducing tumor growth in mouse xenografts of human BRAF V600E-mutant melanoma.[5] These studies were instrumental in establishing the proof-of-concept for its clinical development.
• Off-Target Kinase Activity: While highly selective for BRAF, dabrafenib is not entirely specific. At concentrations higher than those required for BRAF inhibition, it can inhibit other kinases. A screening panel of 270 kinases identified inhibitory activity against targets such as LIMK1, ALK5, SIK2, and NEK9.[5] While the clinical relevance of these off-target effects is not fully elucidated, they may contribute to certain aspects of the drug's overall therapeutic and side-effect profile.

3.3 Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

The pharmacokinetic profile of dabrafenib dictates its dosing regimen, food-effect restrictions, and potential for drug-drug interactions.

• Absorption: Dabrafenib is well-absorbed after oral administration, with a high absolute bioavailability of 95%.[32] Peak plasma concentrations ( Tmax​) are typically reached approximately 2 hours after dosing in a fasted state.[1] A critical clinical consideration is a significant negative food effect. Administration with a high-fat meal substantially decreases the extent (AUC) and rate of absorption.[32] Consequently, dabrafenib must be administered on an empty stomach, defined as at least 1 hour before or 2 hours after a meal, to ensure consistent and optimal exposure.[3]
• Distribution: Dabrafenib is extensively bound to human plasma proteins, with a binding fraction of approximately 99.7%.[4] It has an apparent volume of distribution ( Vc​/F) of 70.3 L, indicating distribution beyond the plasma volume into tissues.[1] An important aspect of its distribution is limited penetration into the central nervous system (CNS). Dabrafenib is a substrate for the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), which are highly expressed at the blood-brain barrier and actively pump the drug out of the brain parenchyma.[1] Despite this, the combination therapy has demonstrated clear efficacy in treating low-grade glioma, a type of brain tumor.[9] This apparent contradiction suggests that in the context of a brain tumor, the blood-brain barrier may be partially compromised, or that the concentrations achieved, though limited, are sufficient to exert a powerful therapeutic effect on these highly sensitive tumors.
• Metabolism: Dabrafenib undergoes extensive hepatic metabolism.
• The primary metabolic pathway is oxidation, mediated mainly by cytochrome P450 2C8 (CYP2C8), which accounts for approximately 56-67% of its clearance, and to a lesser extent by CYP3A4 (~24%).[1] This initial step forms hydroxy-dabrafenib, which is an active metabolite with potency similar to the parent drug.[1]
• Hydroxy-dabrafenib is subsequently oxidized by CYP3A4 to form carboxy-dabrafenib, an inactive metabolite.[1]
• Carboxy-dabrafenib can then be non-enzymatically decarboxylated to form desmethyl-dabrafenib, another active metabolite that may be reabsorbed from the gut.[1]
• A key pharmacokinetic feature of dabrafenib is auto-induction. Upon repeated dosing, dabrafenib induces its own metabolism (primarily via induction of CYP3A4), leading to a decrease in systemic exposure (AUC) of about 27% at steady-state compared to what would be predicted from a single dose.[1]
• Excretion: Elimination of dabrafenib and its metabolites occurs primarily through the feces, which accounts for 71% of an administered radioactive dose. A smaller fraction (23%) is excreted in the urine, almost exclusively in the form of metabolites.[1]
• Half-Life: The terminal elimination half-life of dabrafenib is approximately 8 hours following a single oral dose.[1] The active metabolite, hydroxy-dabrafenib, has a parallel half-life of 10 hours. The other active and inactive metabolites, carboxy-dabrafenib and desmethyl-dabrafenib, exhibit longer terminal half-lives of 21-22 hours, which contributes to the sustained pharmacologic effect of the drug despite its twice-daily dosing schedule.[1]

Table 2: Summary of Dabrafenib Pharmacokinetic Parameters

Parameter	Value / Description	Source(s)
Bioavailability (Absolute)	95%	32
Time to Peak Plasma Conc. (Tmax​)	~2 hours (fasted)	1
Effect of Food	High-fat meal decreases AUC and delays absorption; must be taken on an empty stomach.	3
Plasma Protein Binding	~99.7%	4
Volume of Distribution (Vc​/F)	70.3 L	1
Primary Metabolic Enzymes	CYP2C8 (major), CYP3A4 (minor)	1
Active Metabolites	Hydroxy-dabrafenib, Desmethyl-dabrafenib	1
Route of Elimination	Feces (71%), Urine (23%) - primarily as metabolites	1
Terminal Half-Life (t1/2​)	Dabrafenib: 8 hours	1
	Hydroxy-dabrafenib: 10 hours	1
	Carboxy-/Desmethyl-dabrafenib: 21-22 hours	1

Section 4: Clinical Development and Efficacy

The clinical development program for dabrafenib, particularly in combination with trametinib, has been extensive and highly successful, leading to a series of regulatory approvals that have redefined treatment paradigms across multiple cancer types. Its trajectory from a targeted agent for a single disease to a broad, tumor-agnostic therapy serves as a case study in the evolution of precision oncology.

4.1 Approved Indications, Patient Selection, and Dosage

The use of dabrafenib is strictly guided by the presence of specific genetic biomarkers in the patient's tumor.

Patient Selection

A non-negotiable prerequisite for initiating therapy with dabrafenib, either as a single agent or in combination with trametinib, is the molecular confirmation of a sensitizing BRAF mutation in tumor specimens using an FDA-approved diagnostic test.[8] For most indications, this is the BRAF V600E mutation, while for melanoma, the V600K mutation is also an approved biomarker for combination therapy.[1] Dabrafenib is explicitly contraindicated and not indicated for the treatment of patients with wild-type

BRAF cancers, where it may be ineffective or even promote tumor growth through paradoxical pathway activation.[8]

FDA-Approved Indications

The approved indications for dabrafenib have expanded significantly since its initial launch, reflecting a deliberate strategy of following the science of the BRAF V600 mutation across different histologies. The current FDA-approved uses are summarized in Table 3.

Table 3: Summary of FDA-Approved Indications for Dabrafenib

Cancer Type	Setting	Required BRAF Mutation(s)	Therapy	Patient Population	Source(s)
Melanoma	Unresectable or Metastatic	V600E	Monotherapy	Adult	8
Melanoma	Unresectable or Metastatic	V600E or V600K	Combination w/ Trametinib	Adult	1
Melanoma	Adjuvant (Stage III)	V600E or V600K	Combination w/ Trametinib	Adult	1
Non-Small Cell Lung Cancer (NSCLC)	Metastatic	V600E	Combination w/ Trametinib	Adult	1
Anaplastic Thyroid Cancer (ATC)	Locally Advanced or Metastatic	V600E	Combination w/ Trametinib	Adult	1
Solid Tumors (Tumor-Agnostic)¹	Unresectable or Metastatic	V600E	Combination w/ Trametinib	Adult & Pediatric (≥6 years)	10
Low-Grade Glioma (LGG)	Requires Systemic Therapy	V600E	Combination w/ Trametinib	Pediatric (≥1 year)	10

¹ This indication was approved under the FDA's Accelerated Approval program. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials. [10]

Dosage and Administration

• Adults: The standard recommended dosage of dabrafenib is 150 mg (administered as two 75 mg capsules) taken orally twice daily, with doses spaced approximately 12 hours apart.[3]
• Pediatric Patients: For pediatric indications, the dosage of dabrafenib is weight-based to ensure appropriate exposure. Dosing can be achieved using either the capsules (for older children who can swallow them) or the tablets for oral suspension (for younger children).[11]
• Administration: To ensure optimal bioavailability, all doses of dabrafenib must be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.[3] When used in combination, the once-daily dose of trametinib is taken at the same time as either the morning or evening dose of dabrafenib.[33]

4.2 Efficacy in Metastatic Melanoma (Pivotal Trials: COMBI-d & COMBI-v)

The role of dabrafenib plus trametinib in first-line metastatic melanoma was established by two large, randomized Phase III trials: COMBI-d (NCT01584648) and COMBI-v (NCT01597908).

• Study Designs:
• COMBI-d: Randomized 423 patients with BRAF V600E/K-mutant metastatic melanoma to receive either dabrafenib plus trametinib or dabrafenib plus placebo.[35]
• COMBI-v: Randomized 704 patients with BRAF V600E/K-mutant metastatic melanoma to receive either dabrafenib plus trametinib or vemurafenib monotherapy, another potent BRAF inhibitor.[3]
• Key Efficacy Findings:
• Both trials demonstrated the superiority of the combination therapy over BRAF inhibitor monotherapy. In COMBI-d, the combination significantly improved progression-free survival (PFS) compared to dabrafenib alone (median PFS 9.3 vs. 8.8 months; HR 0.75) and also showed an interim overall survival (OS) benefit.[35] In COMBI-v, the combination was superior to vemurafenib, with patients living an average of 25.6 months versus 18 months.[3]
• A landmark pooled analysis of these two trials provided long-term follow-up data on 563 patients treated with first-line dabrafenib plus trametinib.[16] With a median follow-up of 22 months, the analysis revealed a durable, long-term benefit for a substantial subset of patients. The 5-year progression-free survival rate was 19%, and the 5-year overall survival rate was 34%.[16]
• This analysis highlighted that approximately one-third of patients with this historically aggressive disease could achieve long-term survival with first-line targeted therapy. A critical factor associated with this durable benefit was the achievement of a complete response (CR). Patients who achieved a CR (19% of the total cohort) had a remarkable 5-year OS rate of 71%.[16]
• Baseline prognostic factors were also identified. Patients with a normal lactate dehydrogenase (LDH) level and metastasis in fewer than three organ sites at the start of therapy had a significantly better long-term outcome, with a 5-year OS rate of 55% in this favorable-risk subgroup.[16]

4.3 Efficacy in Adjuvant Melanoma (Pivotal Trial: COMBI-AD)

The COMBI-AD trial (NCT01682083) was a practice-defining study that evaluated the role of dabrafenib plus trametinib in the adjuvant (post-surgical) setting for patients at high risk of recurrence.

• Study Design: This large, double-blind, placebo-controlled Phase III trial randomized 870 patients with completely resected Stage III melanoma harboring a BRAF V600E or V600K mutation. Patients received either 12 months of dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or matched placebos.[3]
• Relapse-Free Survival (RFS): The primary endpoint of the trial was RFS, and the results were unequivocally positive. The combination therapy demonstrated a profound and durable reduction in the risk of disease recurrence or death. At the final analysis, with a median follow-up of over 8 years, the combination reduced the risk of relapse or death by 48% compared to placebo (Hazard Ratio 0.52; 95% CI, 0.43-0.63).[15] The median RFS was extended dramatically from 16.6 months in the placebo arm to 93.1 months in the combination arm.[39] At the 8-year mark, 50% of patients in the combination arm remained relapse-free, compared to only 35% in the placebo arm.[39]
• Distant Metastasis-Free Survival (DMFS): The combination therapy also significantly reduced the risk of developing distant metastases, the most lethal form of recurrence. The risk of distant metastasis or death was reduced by 44% (HR 0.56; 95% CI, 0.44-0.71).[39]
• Overall Survival (OS): The interpretation of the OS data from COMBI-AD requires nuance. At the final analysis, a clear separation in the Kaplan-Meier survival curves was observed, favoring the combination therapy. This translated to a 20% reduction in the risk of death from any cause (HR 0.80) and an 8-year OS rate of 71% versus 65% for placebo.[39] However, this result did not meet the prespecified threshold for statistical significance (p=0.063).[39] This outcome does not necessarily imply a lack of survival benefit. It reflects the complexities of modern oncology trials with long follow-up, where the availability of highly effective subsequent therapies (such as immune checkpoint inhibitors) for patients who relapsed in the placebo arm can confound and dilute the observable OS difference between the initial treatment strategies. The clinically meaningful 20% reduction in the risk of death remains a powerful indicator of the combination's long-term benefit.
• Subgroup Analysis: The therapeutic benefit in terms of RFS, DMFS, and OS was consistent across nearly all prespecified subgroups, including those with the BRAF V600E mutation (HR for OS 0.75). The benefit was less clear in the much smaller subgroup of patients with the BRAF V600K mutation, though this finding is limited by the small sample size.[39]

Table 4: Key Efficacy Outcomes from Pivotal Melanoma Trials

Trial Name	Patient Population	Treatment Arms	Primary Endpoint	Hazard Ratio (95% CI)	Key Secondary/Long-Term Outcomes	Source(s)
COMBI-d	Metastatic Melanoma (BRAF V600E/K)	D+T vs. D+Placebo	PFS	0.75 (0.57-0.99)	5-Year Pooled OS Rate: 34%	16
COMBI-v	Metastatic Melanoma (BRAF V600E/K)	D+T vs. Vemurafenib	OS	Not directly reported in snippets	Median OS: 25.6 months (D+T) vs. 18.0 months (Vemurafenib)	3
COMBI-AD	Adjuvant Melanoma (Stage III, BRAF V600E/K)	D+T vs. Placebo	RFS	0.52 (0.43-0.63)	8-Year RFS: 50% vs 35% 8-Year OS: 71% vs 65% (HR 0.80; p=0.063)	15

D=Dabrafenib; T=Trametinib; PFS=Progression-Free Survival; OS=Overall Survival; RFS=Relapse-Free Survival

4.4 Efficacy in NSCLC, ATC, and Tumor-Agnostic/Pediatric Settings

The success of dabrafenib plus trametinib in melanoma provided the foundation for its investigation in other BRAF V600E-driven cancers.

• Non-Small Cell Lung Cancer (NSCLC): The approval for metastatic NSCLC was based on the multi-cohort, non-randomized Study BRF113928 (NCT01336634).[42] In patients who had received prior chemotherapy, the combination therapy produced an overall response rate (ORR) of 63%. In the treatment-naïve, first-line setting, the ORR was 61%, demonstrating robust activity regardless of prior treatment history.[3]
• Anaplastic Thyroid Cancer (ATC): ATC is an extremely aggressive and rare cancer with a dismal prognosis. In an open-label trial of patients with BRAF V600E-mutated ATC, the dabrafenib-trametinib combination was the first regimen to demonstrate potent and meaningful clinical activity, leading to its approval for this orphan disease where no other satisfactory options existed.[1]
• Tumor-Agnostic Solid Tumors: The landmark tumor-agnostic approval was granted based on data pooled from several basket trials, including the adult ROAR (NCT02034110) and NCI-MATCH (NCT02465060) trials, and a pediatric study.[12] In a cohort of 131 adult patients with 24 different types of BRAF V600E-mutated tumors (excluding colorectal cancer), the combination achieved an ORR of 41%. Significant activity was observed in several rare cancers, including biliary tract cancer (ORR 46%), high-grade glioma (ORR 33%), and low-grade glioma (ORR 50%).[12] This approval codified the principle that the underlying genetic driver, not the tissue of origin, can be the primary determinant of treatment selection.
• Pediatric Low-Grade Glioma (LGG): The approval in pediatric LGG represented a major breakthrough. The pivotal trial, Study CDRB436G2201 (NCT02684058), directly compared dabrafenib plus trametinib against the standard-of-care chemotherapy regimen of carboplatin plus vincristine in children aged 1 year and older with BRAF V600E-mutant LGG requiring first-line systemic therapy.[14] The results were overwhelmingly in favor of the targeted therapy. The ORR was 46.6% for the dabrafenib-trametinib arm, compared to just 10.8% for the chemotherapy arm. This translated into a dramatic improvement in PFS, with a median of 20.1 months for the combination versus 7.4 months for chemotherapy (HR 0.31), representing a 69% reduction in the risk of progression or death.[14] These results immediately established dabrafenib plus trametinib as the new global standard of care for this specific pediatric population.

Section 5: Safety and Tolerability Profile

The safety profile of dabrafenib is well-characterized and manageable, but it requires careful monitoring and patient education. The profile differs notably between monotherapy and the more commonly used combination therapy with trametinib.

5.1 Common and Serious Adverse Reactions

• Dabrafenib Monotherapy: The most frequently reported adverse reactions (affecting more than 1 in 10 people) are primarily dermatologic and constitutional. These include hyperkeratosis (thickening of the skin), headache, pyrexia (fever), arthralgia (joint pain), papilloma (wart-like skin growths), alopecia (hair loss), and palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome).[3]
• Dabrafenib in Combination with Trametinib: The safety profile of the combination therapy is distinct. While some toxicities like hyperproliferative skin lesions are reduced, others are more frequent and/or severe. The most common adverse reactions (affecting more than 1 in 5 people) with the combination are pyrexia, fatigue, nausea, chills, headache, diarrhea, vomiting, arthralgia, and rash.[3]
• Increased Incidence and Severity with Combination Therapy: It is a critical and somewhat non-obvious clinical finding that while the combination is more effective, it is associated with a higher incidence and greater severity of certain adverse events compared to dabrafenib monotherapy. These notably include pyrexia, chills, diarrhea, vomiting, and peripheral edema.[11] This suggests that while MEK inhibition mitigates the paradoxical activation that drives skin cancers, the dual pathway blockade may dysregulate other homeostatic signaling systems, particularly those involved in inflammatory and thermoregulatory responses.

Table 5: Common and Serious Adverse Reactions Associated with Dabrafenib Therapy

System Organ Class	Adverse Reaction	Frequency in Monotherapy (≥20%)	Frequency in Combination Therapy (≥20%)	Source(s)
Skin and Subcutaneous Tissue	Hyperkeratosis	>10%	<20%	3
	Papilloma	>10%	<20%	3
	Alopecia	>10%	<20%	3
	Palmar-plantar erythrodysesthesia	>10%	<20%	3
	Rash	>10%	>20%	3
	Dry Skin	-	>20%	11
General Disorders	Pyrexia (Fever)	>10%	>20% (up to 63%)	3
	Fatigue	>10%	>20%	3
	Chills	-	>20%	3
	Peripheral Edema	-	>20%	11
Nervous System	Headache	>10%	>20%	3
Musculoskeletal	Arthralgia (Joint Pain)	>10%	>20%	3
	Myalgia (Muscle Pain)	-	>20%	11
Gastrointestinal	Nausea	>10%	>20%	3
	Vomiting	>10%	>20%	3
	Diarrhea	>10%	>20%	3
	Decreased Appetite	-	>20%	11
Respiratory	Cough	>10%	>20%	11

Frequencies are approximate based on prescribing information categories (e.g., ">1 in 10 people" or ">1 in 5 people") and specific trial data.

5.2 Warnings, Precautions, and Risk Management

The prescribing information for dabrafenib includes several important warnings and precautions that require active management. Many of these toxicities are directly linked to the on-target effects of MAPK pathway inhibition in various tissues.

• New Primary Malignancies:
• Cutaneous Malignancies: As a direct result of paradoxical MAPK activation, dabrafenib monotherapy is associated with a high risk of developing new cutaneous squamous cell carcinomas (cuSCC) and keratoacanthomas. The combination with trametinib significantly reduces this risk.[17] All patients should undergo a dermatologic evaluation prior to starting therapy, every 2 months during therapy, and for up to 6 months after discontinuation.[11]
• Non-Cutaneous Malignancies: Cases of new primary non-cutaneous malignancies, particularly those associated with RAS mutations, have been reported. Dabrafenib should be permanently discontinued if a RAS-mutant non-cutaneous malignancy develops.[29]
• Hemorrhage: The combination of dabrafenib and trametinib can cause serious and sometimes fatal bleeding events, including intracranial, gastrointestinal, and retroperitoneal hemorrhages. The risk may be elevated in patients with brain metastases or those receiving concomitant anticoagulant or antiplatelet therapy.[7]
• Cardiomyopathy: A reduction in left ventricular ejection fraction (LVEF) can occur. LVEF should be measured by echocardiogram or MUGA scan before initiating treatment, one month after starting, and then every 2 to 3 months thereafter for the duration of treatment.[18] Dose interruption, reduction, or discontinuation may be necessary based on the degree of LVEF decline.
• Uveitis and Ocular Toxicities: Ocular side effects, including uveitis, iritis, and iridocyclitis, are known risks. Patients should be advised to report any visual changes, such as blurred vision, eye pain, or photophobia, immediately. Prompt ophthalmologic evaluation is required, and treatment may involve topical steroids and interruption of dabrafenib.[29]
• Serious Febrile Reactions (Pyrexia): Fever is one of the most common and clinically significant toxicities of dabrafenib, and its incidence and severity are markedly increased with the addition of trametinib.[7] These febrile reactions can be severe, accompanied by rigors, chills, hypotension, dehydration, and acute renal insufficiency. Management involves interrupting therapy, administering antipyretics, and ensuring adequate hydration. For recurrent or severe fevers, dose reduction or the use of corticosteroids may be necessary.[11]
• Serious Skin Toxicities: In addition to cuSCC, other severe cutaneous adverse reactions (SCARs) have been reported with the combination therapy, including life-threatening conditions like Stevens-Johnson syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Any patient developing a severe or worsening rash should be evaluated promptly.[18]
• Hyperglycemia: Dabrafenib can cause elevated blood glucose levels. Patients with pre-existing diabetes may require more intensive monitoring and adjustment of their anti-diabetic medications. New-onset hyperglycemia can also occur.[17]
• Embryo-Fetal Toxicity: Dabrafenib can cause harm to a developing fetus. It is contraindicated for use during pregnancy. Females of reproductive potential must use a highly effective, non-hormonal method of contraception during treatment and for at least 2 weeks after the final dose of dabrafenib (or 16 weeks after the final dose of trametinib, if used in combination). This is because dabrafenib can induce metabolic enzymes that may render hormonal contraceptives ineffective.[17]

Section 6: Clinically Significant Drug-Drug Interactions (DDI)

The metabolic profile of dabrafenib makes it susceptible to and a perpetrator of numerous clinically significant drug-drug interactions. Its complex DDI profile, where it acts as both a victim of metabolic inhibition and a perpetrator of metabolic induction, necessitates a mandatory and thorough medication review for any patient initiating therapy.

6.1 Dabrafenib as a Metabolic "Victim"

Dabrafenib's clearance is highly dependent on specific cytochrome P450 enzymes, making it vulnerable to interactions with drugs that inhibit these pathways.

• Interaction with CYP3A4 and CYP2C8 Inhibitors: Dabrafenib is a substrate of both CYP3A4 and, more importantly, CYP2C8.[1] Co-administration with drugs that are strong inhibitors of either of these enzymes can significantly increase the plasma concentrations of dabrafenib and its active metabolites. This elevated exposure increases the risk of dose-related toxicities.
• Examples of Inhibitors: Strong CYP3A4 inhibitors include ketoconazole, itraconazole, clarithromycin, and ritonavir. A strong CYP2C8 inhibitor is gemfibrozil.
• Clinical Management: Concomitant use of dabrafenib with strong inhibitors of CYP3A4 or CYP2C8 should be avoided. If co-administration is medically necessary, patients should be monitored closely for adverse reactions. Alternative medications with no or minimal inhibitory potential should be considered.[34]

6.2 Dabrafenib as a Metabolic "Perpetrator"

Perhaps more clinically challenging is dabrafenib's role as a potent inducer of multiple drug-metabolizing enzymes. This can lead to the therapeutic failure of a wide range of co-administered medications.

• Induction of Metabolic Enzymes: Dabrafenib has been shown to be an inducer of several key enzymes, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and UDP-glucuronosyltransferases (UGTs).[34] This induction effect increases the metabolic clearance of drugs that are substrates for these enzymes.
• Clinical Consequences:
• Hormonal Contraceptives: The induction of CYP3A4 by dabrafenib can significantly accelerate the metabolism of estrogen- and progestin-based oral contraceptives, rendering them ineffective. This is a critical interaction, as dabrafenib is teratogenic. Female patients of reproductive potential must be counseled to use a highly effective, alternative, non-hormonal method of contraception during treatment and for the recommended period after discontinuation.[18]
• Warfarin: Warfarin is a substrate of CYP2C9. Co-administration with dabrafenib can decrease warfarin exposure, leading to a subtherapeutic anticoagulant effect and an increased risk of thrombosis. The International Normalized Ratio (INR) should be monitored more frequently upon initiation and discontinuation of dabrafenib, and the warfarin dose should be adjusted accordingly.[36]
• Immunosuppressants: A published case report has documented a clinically significant interaction in a heart transplant patient, where the initiation of dabrafenib led to a sharp decrease in the blood levels of the immunosuppressants everolimus and tacrolimus (both CYP3A4 substrates). This required substantial dose increases of the immunosuppressants to maintain therapeutic levels and prevent graft rejection.[45] This provides a stark real-world example of the potential harm from dabrafenib's induction effect.
• Other CYP3A4 Substrates: A wide variety of other drugs are metabolized by CYP3A4, including certain statins (e.g., atorvastatin), calcium channel blockers, and corticosteroids like dexamethasone. Co-administration with dabrafenib may reduce their efficacy.

6.3 Other Interactions

• Drugs Affecting Gastric pH: Dabrafenib's solubility is pH-dependent, being practically insoluble at a pH above 4.[4] Therefore, drugs that raise the gastric pH, such as proton pump inhibitors (e.g., omeprazole), H2-receptor antagonists (e.g., ranitidine), and antacids, have the potential to decrease the dissolution and absorption of dabrafenib. While the clinical significance of this interaction requires further study, caution is advised, and concomitant use should be managed thoughtfully.[36]

Table 6: Clinically Significant Drug-Drug Interactions with Dabrafenib

Interacting Drug/Class	Mechanism of Interaction	Clinical Effect	Recommended Clinical Management	Source(s)
Strong CYP3A4/CYP2C8 Inhibitors (e.g., ketoconazole, gemfibrozil)	Inhibition of dabrafenib metabolism	Increased dabrafenib concentration and risk of toxicity	Avoid concomitant use. If unavoidable, monitor closely for adverse reactions.	34
Strong CYP3A4/CYP2C8 Inducers (e.g., rifampin, carbamazepine)	Induction of dabrafenib metabolism	Decreased dabrafenib concentration and potential loss of efficacy	Avoid concomitant use. Select alternative agents with no or minimal induction potential.	36
Substrates of CYP3A4/CYP2C9 (e.g., midazolam, warfarin, hormonal contraceptives)	Dabrafenib induces the metabolism of the substrate drug	Decreased concentration and efficacy of the concomitant drug	Avoid concomitant use where efficacy is critical (e.g., hormonal contraceptives). Monitor drug effect (e.g., INR for warfarin) and consider dose adjustments.	18
Drugs Affecting Gastric pH (e.g., Proton Pump Inhibitors)	Decreased dabrafenib solubility due to increased gastric pH	Potential for decreased dabrafenib absorption and efficacy	Consider spacing administration times or using alternative agents. Clinical significance is not fully established.	4

Section 7: Regulatory and Market Analysis

Dabrafenib (Tafinlar®) is a major pharmaceutical product with a complex regulatory history and a robust intellectual property portfolio that shapes its market position and commercial lifecycle.

7.1 Regulatory History and Approvals

Dabrafenib was originally developed by GlaxoSmithKline (GSK) and received its first FDA approval in 2013. In 2015, as part of a major asset swap, the rights to dabrafenib and other oncology products were transferred to Novartis Pharmaceuticals Corporation, which now markets the drug globally.[7]

The regulatory journey of dabrafenib is a showcase of strategic lifecycle management and the successful expansion of a biomarker-driven therapy. It progressed from an initial approval in a specific cancer subtype to broader applications in adjuvant settings, other cancer histologies, and ultimately, a tumor-agnostic indication. This trajectory highlights a deliberate and successful strategy of following the scientific evidence of the BRAF V600 mutation across diverse clinical contexts.

Table 7: Timeline of Key FDA Regulatory Approvals for Dabrafenib

Approval Date	Indication	Therapy	Key Supporting Trial(s)	Source(s)
May 29, 2013	Unresectable or Metastatic Melanoma (BRAF V600E)	Monotherapy	BREAK-3	31
January 9, 2014	Unresectable or Metastatic Melanoma (BRAF V600E/K)	Combination w/ Trametinib	COMBI-d (NCT01584648)	33
June 22, 2017	Metastatic NSCLC (BRAF V600E)	Combination w/ Trametinib	Study BRF113928 (NCT01336634)	42
April 30, 2018	Adjuvant Treatment of Melanoma (Stage III, BRAF V600E/K)	Combination w/ Trametinib	COMBI-AD (NCT01682083)	44
May 4, 2018	Anaplastic Thyroid Cancer (BRAF V600E)	Combination w/ Trametinib	Open-label Phase II Study	44
June 22, 2022	Unresectable or Metastatic Solid Tumors (BRAF V600E)	Combination w/ Trametinib	ROAR (NCT02034110), NCI-MATCH (NCT02465060)	12
March 16, 2023	Pediatric Low-Grade Glioma (BRAF V600E)	Combination w/ Trametinib	Study CDRB436G2201 (NCT02684058)	14

7.2 Patent Status and Market Exclusivity

The commercial value and market longevity of Tafinlar® are protected by a formidable intellectual property (IP) framework, comprising numerous patents and regulatory exclusivities. This framework is not defined by a single expiration date but rather by a "patent thicket"—a dense, overlapping web of patents covering various aspects of the drug. This is a common and deliberate pharmaceutical strategy designed to extend a product's commercial life well beyond the expiration of its foundational composition-of-matter patent, thereby delaying the entry of generic competition.

• Patent Portfolio: Tafinlar® is protected by at least 16 active US drug patents that cover not only the dabrafenib molecule itself but also its mesylate salt form, pharmaceutical compositions, methods of use for specific indications (e.g., melanoma, NSCLC), and, crucially, its use in combination with trametinib.[47]
• Key Patent Expirations: The expiration dates for this portfolio are staggered over more than a decade.
• The primary composition-of-matter patents (e.g., US 7,994,185) that protect the dabrafenib chemical entity are expected to expire around 2029-2030 in the US and EU, a timeline that includes pediatric extensions.[48]
• However, subsequent patents covering the combination therapy with trametinib, methods for adjuvant treatment, and specific pharmaceutical formulations extend market protection significantly further. The latest-expiring patents currently listed in the FDA's Orange Book for Tafinlar® have expiration dates extending to December 2038.[47]
• Regulatory Exclusivities: In addition to patent protection, Tafinlar® has been granted multiple forms of regulatory exclusivity by the FDA. These include New Chemical Entity (NCE) exclusivity (expired in 2018), multiple Orphan Drug Exclusivities (ODE) for its various rare disease indications, and Pediatric Exclusivity (PED), which adds six months to existing patent and exclusivity terms. The last outstanding ODE is set to expire in 2030, further securing its market position for that indication.[47]
• Patent Litigation: The high commercial value of BRAF inhibitors has led to intense competition and significant legal disputes. A notable case involved a patent infringement lawsuit filed by Plexxikon (a subsidiary of Daiichi Sankyo), the developer of the competing BRAF inhibitor vemurafenib (Zelboraf®), against Novartis. Plexxikon argued that GSK/Novartis's Tafinlar® infringed on its earlier and broader patents covering BRAF inhibitor compounds, which were filed in 2005.[46] In 2021, a U.S. jury ruled in favor of Plexxikon, finding the infringement to be willful and awarding substantial damages.[46] The protracted legal battle was ultimately resolved in December 2023, when Novartis agreed to a settlement, paying a lump sum of approximately $182 million to Daiichi Sankyo.[51] This case underscores the high-stakes legal environment in the kinase inhibitor space and the material risks associated with freedom-to-operate in a crowded field.

Table 8: Selected Dabrafenib Patent and Exclusivity Landscape in the U.S.

Patent Number	Type / Key Claims	Estimated Expiration Date	Source(s)
US 7,994,185	Composition of Matter (Benzene sulfonamide thiazole compounds)	July 20, 2030 (incl. PED)	49
US 8,952,018	Method of Use (Pharmaceutical combination of MEK and B-RAF inhibitors)	April 15, 2031 (incl. PED)	47
US 10,869,869	Method of Use (Method of adjuvant cancer treatment)	February 28, 2034 (incl. PED)	47
US 11,504,333	Formulation (Pharmaceutical composition)	December 29, 2038 (incl. PED)	47
Exclusivity Type	Indication	Expiration Date	Source(s)
Orphan Drug (ODE)	Anaplastic Thyroid Cancer	May 4, 2025	47
New Indication (I-894)	Unresectable/Metastatic Solid Tumors	June 22, 2025	47
Orphan Drug (ODE)	Pediatric Low-Grade Glioma	March 16, 2030	47

PED = Pediatric Exclusivity. Dates are subject to change based on litigation or other regulatory actions.

Section 8: Synthesis and Concluding Remarks

Dabrafenib, as a central component of the Tafinlar® plus Mekinist® combination therapy, stands as a testament to the power of rational drug design and the success of the precision oncology movement. Its clinical development and application have fundamentally altered the natural history and prognosis for patients whose cancers are driven by BRAF V600 mutations. By selectively targeting the core oncogenic driver, dabrafenib provides a highly effective therapeutic option that has established new standards of care across a remarkable breadth of diseases.

The impact on clinical practice has been profound. In melanoma, the combination therapy has transformed the landscape, offering durable long-term survival to a meaningful subset of patients with metastatic disease and significantly reducing the risk of recurrence in the high-risk adjuvant setting. Its expansion into BRAF V600E-mutant non-small cell lung cancer and anaplastic thyroid cancer provided the first effective targeted therapies for these patient populations. Most notably, its approvals as a tumor-agnostic agent for any solid tumor with the requisite mutation and as a superior alternative to chemotherapy for pediatric low-grade glioma have solidified its role as a versatile and indispensable tool in the oncologist's armamentarium.

Despite these successes, significant challenges remain. The foremost of these is the near-inevitable development of acquired resistance in the majority of patients with metastatic disease. While the combination with trametinib delays this process compared to monotherapy, tumor cells eventually find alternative signaling pathways to bypass the MAPK blockade. Furthermore, while the long-term data from the COMBI-AD adjuvant trial showed a clinically meaningful reduction in the risk of death, the lack of statistical significance for the overall survival endpoint leaves room for debate and ongoing comparison with adjuvant immunotherapy, which has a different mechanism of action and toxicity profile.

The future of treatment for BRAF-mutant cancers will focus on addressing these challenges. Key future directions in clinical research include:

• Overcoming Resistance: Investigating triplet therapies that combine BRAF/MEK inhibition with other targeted agents or, more prominently, with immune checkpoint inhibitors. The goal is to attack the tumor through multiple, non-overlapping mechanisms to prevent or overcome resistance.
• Optimizing Sequencing: A central question in the management of BRAF-mutant melanoma is the optimal sequence of therapy. Clinical trials are ongoing to determine whether patients benefit more from initial treatment with targeted therapy (dabrafenib/trametinib) followed by immunotherapy at progression, or the reverse sequence.[53]
• Expanding the Tumor-Agnostic Role: As comprehensive genomic profiling becomes a routine part of cancer diagnostics, the tumor-agnostic role of dabrafenib will likely continue to expand. Its efficacy will be explored in ever-rarer cancer types that harbor the BRAF V600E mutation, offering hope to patients with limited or no other treatment options.

In conclusion, dabrafenib is a landmark achievement in modern pharmacology. It exemplifies a therapeutic strategy that is potent, biomarker-driven, and broadly applicable across diverse cancer histologies. While the ongoing challenges of drug resistance and the evolving therapeutic landscape necessitate continuous research and innovation, dabrafenib's established efficacy and its central role in the highly synergistic combination with trametinib have secured its place as a cornerstone of precision cancer medicine, delivering transformative benefits to patients worldwide.

Works cited

1. Dabrafenib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB08912
2. Dabrafenib | 99.99%(HPLC) | In Stock | Raf inhibitor - Selleck Chemicals, accessed July 21, 2025, https://www.selleckchem.com/products/dabrafenib-gsk2118436.html
3. Tafinlar | European Medicines Agency (EMA), accessed July 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar
4. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TAFINLAR safely and effe - Novartis, accessed July 21, 2025, https://www.novartis.com/us-en/sites/novartis_us/files/tafinlar.pdf
5. Dabrafenib (GSK2118436, CAS Number: 1195765-45-7) | Cayman Chemical, accessed July 21, 2025, https://www.caymanchem.com/product/16989/dabrafenib
6. us.tafinlarmekinist.com, accessed July 21, 2025, https://us.tafinlarmekinist.com/#:~:text=TAFINLAR%C2%AE%20(dabrafenib)%20%2B%20MEKINIST,(trametinib)%20%7C%20DTC%20and%20HCP
7. Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up, accessed July 21, 2025, https://www.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrate-superior-overall-survival-benefit-advanced-melanoma-patients-three-year-follow
8. This label may not be the latest approved by FDA. For current ..., accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s019lbl.pdf
9. Dabrafenib - brand name list from Drugs.com, accessed July 21, 2025, https://www.drugs.com/ingredient/dabrafenib.html
10. Annotation of FDA Label for dabrafenib and BRAF - PharmGKB, accessed July 21, 2025, https://www.pharmgkb.org/labelAnnotation/PA166114912
11. TAFINLAR® (dabrafenib) capsules, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf
12. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation, accessed July 21, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid
13. FDA approves dabrafenib–trametinib for BRAF-positive cancers - NCI, accessed July 21, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors
14. FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation, accessed July 21, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation
15. Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma, accessed July 21, 2025, https://www.targetedonc.com/view/dr-long-highlights-long-term-benefit-of-dabrafenib-trametinib-in-melanoma
16. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/31166680/
17. Dabrafenib (oral route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/dabrafenib-oral-route/description/drg-20061178
18. daBRAFenib - Cancer Care Ontario, accessed July 21, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44326
19. TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) | DTC and HCP, accessed July 21, 2025, https://us.tafinlarmekinist.com/
20. CAS 1195765-45-7 Dabrafenib - BOC Sciences, accessed July 21, 2025, https://bio-fermen.bocsci.com/product/dabrafenib-cas-1195765-45-7-454193.html
21. Dabrafenib | C23H20F3N5O2S2 | CID 44462760 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib
22. Dabrafenib free base | GSK2118436 | CAS#1195768-06-9 | CAS#1195765-45-7 | MedKoo Biosciences, accessed July 21, 2025, https://www.medkoo.com/products/4470
23. Dabrafenib mesylate | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/salts/DBSALT000036
24. Dabrafenib | C23H20F3N5O2S2 - ChemSpider, accessed July 21, 2025, https://www.chemspider.com/Chemical-Structure.25948204.html
25. Dabrafenib, mutant B-Raf V600E inhibitor (CAS 1195765-45-7) (ab222019) | Abcam, accessed July 21, 2025, https://www.abcam.com/en-us/products/biochemicals/dabrafenib-mutant-b-raf-v600e-inhibitor-ab222019
26. en.wikipedia.org, accessed July 21, 2025, https://en.wikipedia.org/wiki/Dabrafenib
27. Dabrafenib (GSK2118436) #91942 - Cell Signaling Technology, accessed July 21, 2025, https://www.cellsignal.com/products/activators-inhibitors/dabrafenib-gsk2118436/91942
28. Dabrafenib mesylate | Raf Kinases - Tocris Bioscience, accessed July 21, 2025, https://www.tocris.com/products/dabrafenib-mesylate_7223
29. Taflinar (dabrafenib) dosing, indications, interactions, adverse effects, and more, accessed July 21, 2025, https://reference.medscape.com/drug/tafinlar-dabrafenib-999853
30. Dabrafenib (Tafinlar) | Cancer information, accessed July 21, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/dabrafenib
31. FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10841289/
32. daBRAFenib - Cancer Care Ontario, accessed July 21, 2025, https://www.cancercareontario.ca/en/system/files_force/dabrafenib.pdf?download=1
33. TAFINLAR (dabrafenib) capsules label - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf
34. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/24748562/
35. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF[V600E/K ]mutation-positive cutaneous melanoma - ASCO, accessed July 21, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT128598
36. Dabrafenib: uses, dosing, warnings, adverse events, interactions - Oncology News Central, accessed July 21, 2025, https://www.oncologynewscentral.com/drugs/monograph/164393-313039/dabrafenib-oral
37. Update Shows Long-Term Benefit With Dabrafenib Plus Trametinib in Advanced Melanoma in COMBI Trials - Targeted Oncology, accessed July 21, 2025, https://www.targetedonc.com/view/update-shows-longterm-benefit-with-dabrafenib-plus-trametinib-in-advanced-melanoma-in-combi-trials
38. Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma Final Results of the COMBI-AD Trial - The ASCO Post, accessed July 21, 2025, https://ascopost.com/issues/september-25-2024/adjuvant-dabrafenib-plus-trametinib-for-stage-iii-braf-v600-mutated-melanoma-final-results-of-the-combi-ad-trial/
39. Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma - Oncology Nursing News, accessed July 21, 2025, https://www.oncnursingnews.com/view/adjuvant-dabrafenib-trametinib-maintains-long-term-survival-benefit-in-stage-iii-melanoma
40. Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma - CancerNetwork, accessed July 21, 2025, https://www.cancernetwork.com/view/dabrafenib-trametinib-yields-sustained-survival-during-long-term-follow-up-in-advanced-melanoma
41. Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. | Journal of Clinical Oncology - ASCO Publications, accessed July 21, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.9500
42. FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation - Florida Society of Clinical Oncology, accessed July 21, 2025, https://flasco.org/fda-grants-regular-approval-dabrafenib-trametinib-combination-metastatic-nsclc-braf-v600e-mutation/
43. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors - ASCO Publications, accessed July 21, 2025, https://ascopubs.org/doi/10.1200/EDBK_404770
44. Tafinlar (dabrafenib) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/tafinlar.html
45. Drug interaction between dabrafenib and immunosuppressive drugs: about one case, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/27399255/
46. Novartis on the hook for $178M after losing Tafinlar patent fight with Daiichi's Plexxikon business | Fierce Pharma, accessed July 21, 2025, https://www.fiercepharma.com/pharma/patent-infringement-case-against-novartis-jury-rules-for-plexxikon-awarding-178m
47. Tafinlar patent expiration - Pharsight, accessed July 21, 2025, https://pharsight.greyb.com/drug/tafinlar-patent-expiration
48. gabi-journal.net, accessed July 21, 2025, https://gabi-journal.net/overview-of-the-patent-expiry-of-non-tyrosine-kinase-inhibitors-approved-for-clinical-use-in-the-eu-and-usa.html#:~:text=It%20was%20authorized%20by%20EMA%20in%20August%202013%20and%20the,well%20as%20in%20the%20EU.
49. Drugs covered by patent 7,994,185. Claims, international patent equivalents, patent expiration dates, and generic entry - DrugPatentWatch, accessed July 21, 2025, https://www.drugpatentwatch.com/p/patent/7994185
50. Generic Tafinlar Availability - Drugs.com, accessed July 21, 2025, https://www.drugs.com/availability/generic-tafinlar.html
51. Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case - BioSpace, accessed July 21, 2025, https://www.biospace.com/daiichi-sankyo-reaches-182m-settlement-with-novartis-in-tafinlar-patent-case
52. WO2016059548A1 - Processes for the preparation of dabrafenib - Google Patents, accessed July 21, 2025, https://patents.google.com/patent/WO2016059548A1/un
53. Study Details | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma | ClinicalTrials.gov, accessed July 21, 2025, https://www.clinicaltrials.gov/study/NCT02858921
54. Record History | ver. 894: 2023-09-23 | NCT02224781 | ClinicalTrials.gov, accessed July 21, 2025, https://www.clinicaltrials.gov/study/NCT02224781?tab=history&a=894